UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):

 

October 28, 2003

 

GILEAD SCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

DELAWARE

 

0-19731

 

94-3047598

(State or other jurisdiction of
incorporation or organization)

 

(Commission File Number)

 

(I.R.S. Employer
Identification No.)

 

 

 

 

 

333 LAKESIDE DRIVE, FOSTER CITY, CALIFORNIA

(Address of principal executive offices) 

 

 

 

 

 

94404

(Zip Code)

 

 

 

 

 

(650) 574-3000

(Registrant’s telephone number, including area code)

 

 

 

ITEM 7.            FINANCIAL STATEMENTS AND EXHIBITS

 

(c)           Exhibits

 

Exhibit
Number

 

Description

99.1

 

Press Release, issued by Gilead Sciences, Inc. on October 28, 2003

 

ITEM 12.            RESULTS OF OPERATIONS AND FINANCIAL CONDITION

 

On October 28, 2003, Gilead Sciences, Inc., a Delaware corporation, issued a press release announcing earnings for the quarter and nine months ended September 30, 2003. A copy of the earnings press release is filed as Exhibit 99.1 to this report.

 

Each non-GAAP financial measure presented in the earnings press release is included because our management uses this information to monitor and evaluate on-going operating results and trends excluding certain items.  Our management believes the non-GAAP information is also useful for investors because the in-process research and development charge relating to the acquisition of Triangle Pharmaceuticals, Inc. in January 2003 and the reimbursement to Gilead from the settlement of a contractual dispute with a vendor in September 2003 were the result of transactions that are unusual due to their nature, size and infrequency.  Consequently, excluding these items from our operating results provides users of the financial statements an important insight into our operating results and related trends that affect our core business.

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

GILEAD SCIENCES, INC.

 

(registrant)

 

 

 

/s/John F. Milligan

 

John F. Milligan
Executive Vice President and
Chief Financial Officer

 

Date:                    October 28, 2003

 

3

 

Exhibit Index

 

Exhibit
Number

 

Description

99.1

 

Press Release, issued by Gilead Sciences, Inc. on October 28, 2003

 

4